Corvus Pharmaceuticals, Inc. (CRVS) Tops Q2 EPS by 5c
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Join SI Premium – FREE
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.07), $0.05 better than the analyst estimate of ($0.12).
For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
- Southern Co. (SO) PT Lowered to $99 at Jefferies
- Devon Energy (DVN) PT Lowered to $67 at Wolfe Research: Activist Toms interest positive
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
